** Shares of Lucid Diagnostics LUCD.O down ~25% to $1.24 in extended trading on equity raise plans
** New York-based commercial-stage subsidiary of PAVmed Inc PAVM.O announces stock offering without disclosing deal size
** With ~90.75 mln shares outstanding, co has about $150 mln market cap
** Stock on Weds finished up 1.9% at $1.65. Shares ended 2024 at 82 cents
** Canaccord Genuity sole bookrunner for proposed offering
** Lucid says it's focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。